Add BrightSurf on Google Email

Combination approach shows promise for treating rare, aggressive cancers

Researchers at UCLA Health Jonsson Comprehensive Cancer Center have shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with advanced small cell bladder cancer and small cell/neuroendocrine prostate cancer. The study found that the combination treatment resul...

Study: Older adult prostate cancer patients are increasingly being overtreated

A new study by Cedars-Sinai reveals that significant percentages of older men with intermediate- and high-risk prostate cancers are being subjected to aggressive treatments that may not extend their lives, highlighting the need for a more personalized approach to cancer treatment. The study suggests that better estimation, communicatio...

SourceCedars-Sinai Medical Center·JournalJAMA Internal Medicine·TypeObservational study·DateNov 11, 2024

New option for treating prostate cancer

A new strategy for treating prostate cancer has been developed by blocking the GP130 signalling pathway, contrary to current medical understanding. The study found that activating GP130 in prostate cells reduces tumour growth and stimulates the immune system to fight cancer cells.

SourceMedical University of Vienna·JournalMolecular Cancer·DateNov 8, 2024

Study suggests a healthy diet may help keep low grade prostate cancer from progressing to more dangerous states during active surveillance

A new study suggests that a healthy diet may help keep low-grade prostate cancer from progressing to more aggressive states in men undergoing active surveillance. The research team led by Johns Hopkins Medicine found that a reduced risk of prostate cancer progression is associated with a healthy diet.

SourceJohns Hopkins Medicine·JournalJAMA Oncology·DateOct 17, 2024

Nanoparticle therapy offers new hope for prostate cancer patients

A groundbreaking study has demonstrated the clinical success of a new nanoparticle-based, laser-guided therapy for prostate cancer treatment. The therapy successfully eliminated cancerous cells in 73% of patients after 12 months while preserving key functions and side effects.

SourceUniversity of Virginia School of Engineering and Applied Science·JournalThe Journal of Urology·TypeRandomized controlled/clinical trial·DateOct 16, 2024

The beneficial effects of fermented black garlic extract on prostate cancer are evaluated

Researchers found that fermented black garlic extract reduced tumor aggressiveness parameters, including cell proliferation, without affecting normal prostate cells. The extract altered key signaling pathways related to inflammation, suggesting its potential as a dietary supplement to prevent or slow down prostate cancer progression.

SourceUniversity of Córdoba·JournalNutrients·TypeExperimental study·DateOct 15, 2024

Using mice to understand the link between prostate cancer and gut bacteria

A recent study published in The Prostate used genetically modified mice to investigate the relationship between gut dysbiosis and prostate cancer. The researchers found that both humans and mice exhibited marked differences in their gut microbiome composition, with certain bacteria positively associated with prostate cancer. Additional...

SourceKindai University·JournalThe Prostate·TypeObservational study·DateOct 7, 2024

Research points to potential new treatment for aggressive prostate cancer subtype

Researchers at Michigan Medicine have discovered a new subtype of aggressive prostate cancer and identified a potential degrader to target it. The study found that a genetic alteration in the CDK12 gene drives cancer development, and a degrader targeting this gene shows promise in destroying cancer cells.

SourceMichigan Medicine - University of Michigan·JournalCell Reports Medicine·TypeExperimental study·DateOct 4, 2024

UCLA at ASTRO: Predicting response to chemoradiotherapy in rectal cancer, 2-year outcomes of MRI-guided radiotherapy for prostate cancer, impact of symptom self-reporting during chemoradiation and more

UCLA investigators presented data on chemoradiotherapy in rectal cancer, MRI-guided radiotherapy for prostate cancer, and symptom self-reporting during treatment. Researchers developed a predictive model to identify patients most likely to respond to chemoradiotherapy in rectal cancer.

Study helps predict how long it will take for testosterone to return to normal after prostate cancer treatment

A new study has found that baseline testosterone, age, and duration of ADT are key predictors of testosterone recovery. The researchers developed a nomogram to estimate recovery times based on patient-specific characteristics, providing valuable insights for improving patient outcomes.

How does cancer spread? Follow the map

Researchers at Cold Spring Harbor Laboratory create a roadmap of how prostate cancer spreads throughout the body, showing that aggressive cells seed cancer's rare migrations to bones, liver, lungs, and lymph nodes. The new technology offers a clearer picture of cancer spread and could lead to more targeted therapeutics.

SourceCold Spring Harbor Laboratory·JournalCancer Discovery·DateSep 25, 2024

Inflammatory cells in tumor microenvironment promote the transformation of prostate cancer cells into treatment-resistant cells

A new study by the University of Eastern Finland found that pro-inflammatory macrophages can transform prostate cancer cells into stem-like cells, making them resistant to treatment. The study reveals that these immune cells secrete factors that increase the expression of stem cell markers in prostate cancer cells.

SourceUniversity of Eastern Finland·JournalOncoImmunology·TypeExperimental study·DateSep 20, 2024

New prostate biopsy technique lowers infection risk

A new prostate biopsy technique, transperineal biopsy, has been shown to lower the risk of infection compared to traditional biopsies. The PREVENT trial found no infections among men who underwent the transperineal procedure, while those with traditional transrectal biopsies had a 1.6% infection rate despite receiving antibiotics.

SourceWeill Cornell Medicine·JournalJAMA Oncology·DateSep 19, 2024

New law regulating out-of-pocket drug spending saves cancer patients more than $7,000 a year, study finds

A new study by Michigan Medicine found that the Inflation Reduction Act's limit on Medicare Part D spending leads to significant savings for cancer patients prescribed oral chemotherapy. The average annual cost for these medications decreased from $11,284 in 2023 to $3,927 in 2024, resulting in median cost savings of $7,260.

SourceMichigan Medicine - University of Michigan·JournalJAMA Network Open·TypeData/statistical analysis·DateSep 10, 2024

Targeted cancer therapies: Getting radioactive atoms to accumulate in tumors

Researchers developed a novel compound to target prostate cancer using radioactive atom astatine-211, potentially overcoming issues with previous compounds like deastatination. The study found high accumulation in tumors and low accumulation in vital organs, highlighting the potential of this new compound for targeted alpha therapy.

SourceChiba University·JournalEJNMMI Radiopharmacy and Chemistry·TypeExperimental study·DateSep 3, 2024

Biologists at HSE University warn of potential errors in microRNA overexpression method

Researchers at HSE University discovered that the microRNA overexpression method may produce incorrect results due to errors in Dicer enzyme cleavage. This can lead to the formation of miRNA isoforms that target unintended genes, resulting in inaccurate conclusions about molecular mechanisms.

SourceNational Research University Higher School of Economics·JournalBiochimica et Biophysica Acta·TypeExperimental study·DateSep 3, 2024

Aston University researcher uses light to develop quicker, cheaper and less painful technique to detect prostate cancer

Aston University researcher has developed a new method of analysing crystals in dehydrated blood samples using polarisation-based image reconstruction technique. The technique showed a 90% accuracy rate for early diagnosis and classification of cancer, making it less traumatic and risky for patients.

SourceAston University·JournalScientific Reports·TypeExperimental study·DateSep 2, 2024

Promising treatment for incurable prostate cancer

Researchers at Flinders University and University of South Australia have discovered a potential breakthrough in treating the most aggressive forms of prostate cancer using CDKI-73, a novel drug inhibitor. The study found that CDKI-73 effectively blocks the growth of prostate cancer cells while sparing normal cells.

SourceFlinders University·JournalBritish Journal of Cancer·TypeRandomized controlled/clinical trial·DateSep 1, 2024

MCG scientists working to understand why men with prostate cancer are at higher risk of Alzheimer’s

Researchers investigated the connection between androgen deprivation therapy for prostate cancer and Alzheimer's disease. They found that ADT can exacerbate cognitive decline by increasing brain immune cell infiltration, but a combination with Natalizumab improved integrity of the blood-brain barrier and reduced inflammation.

Precision therapy for metastatic prostate cancer improves survival

A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.

SourceKarolinska Institutet·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateAug 20, 2024

Mount Sinai researchers discover novel nanoparticles in blood with potential to transform cancer diagnosis

Researchers at Mount Sinai have identified a new class of RNAs packed into tiny particles known as extracellular vesicles that could revolutionize how cancer and other diseases are diagnosed. These molecules undergo changes when cancer is present, suggesting their potential as biomarkers for detecting prostate cancer.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalJournal of Extracellular Vesicles·TypeExperimental study·DateAug 16, 2024

New hope for prostate cancer: new form of immunotherapy could prevent resistance to hormone therapy

Researchers from the University of Sheffield have developed a new form of immunotherapy using nanoparticles that delays the onset of resistance to hormone therapy in prostate cancer. This innovative approach stimulates immune cells called T cells to attack cancer cells, marking a significant breakthrough in treating prostate cancer.

SourceUniversity of Sheffield·JournalBMJ·TypeExperimental study·DateAug 5, 2024

Prostate cancer: Can AI help to avoid unnecessary biopsies?

Researchers have developed an AI-based system that can predict the risk of prostate cancer more accurately than traditional methods. The new tool combines MRI images and deep learning to identify low-risk patients who may not need a biopsy, potentially sparing them from unnecessary procedures and reducing complications.

Study identifies unique treatment preference profiles in men with prostate cancer

Researchers at UCLA Health Sciences identified three distinct patient preference-based profiles among men with low-risk prostate cancer. Despite differences in preferences, physician recommendations played a crucial role in determining treatment choices. The study highlights the need for better integrating patient preferences into trea...

Lower dose prostate cancer treatments retain efficacy while improving tolerability

Researchers found that lower doses of radiopharmaceutical therapy approaches for metastatic castrate-resistant prostate cancer were just as effective as the standard dose, with better tolerability among patients. The study showed improved PSA response rates and comparable median overall survival in both groups.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJul 24, 2024

Prostate cancer blood test equally effective across ethnic groups

A recent study published in Journal of Clinical Oncology has shown that the Stockholm3 prostate cancer blood test is equally effective in detecting clinically significant cancer across different ethnic groups, including African Americans and Asians. The test reduces unnecessary biopsies by 45% while maintaining high detection rates.

SourceKarolinska Institutet·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateJul 23, 2024

Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer

Researchers from Radboud University Medical Center discuss the potential of using early on-treatment circulating tumor DNA measurements as a response assessment for metastatic castration-resistant prostate cancer. The detection of ctDNA at baseline and 4-weeks after treatment initiation can predict response durability to first-line ARPIs.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateJul 17, 2024

Living in disadvantaged neighborhoods influences stress-related genes, which may contribute to aggressive prostate cancer in African American men

A study found that living in disadvantaged neighborhoods is associated with higher stress-related gene activity, which could contribute to aggressive prostate cancer in African American men. The research also linked five genes related to inflammation to an increased risk of prostate cancer.

SourceUniversity of Maryland School of Medicine·JournalJAMA Network Open·TypeObservational study·DateJul 12, 2024